RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

REGENTIS BIOMATERIALS LTD.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 24, 2026

$1.48−0.01 (-0.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

REGENTIS BIOMATERIALS LTD. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
General & Administrative	6.64	0.71	1.13
Operating Income	-6.97	0.93	-1.93
Interest Expense	0.08	0.01	–
Other Non-Operating Income	-6.68	3.87	-2.20
Pretax Income	14	-4.80	4.13
Net Income	-14	4.80	-4.13
EPS (Basic)(per share)	-24.16	1.72	-24.09
EPS (Diluted)(per share)	-24.16	1.72	-24.09
Shares Outstanding (Basic, Weighted)(shares)	0.57	2.77	0.17
Shares Outstanding (Diluted, Weighted)(shares)	0.57	2.77	0.17

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 75.1%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 256.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –